Altheos

Altheos is an early-stage biopharmaceutical company based in the San Francisco Bay area, focusing on the development of innovative small molecule drugs for the treatment of glaucoma. The company gained significant traction in March 2010, securing $20 million in Series A financing led by Bay City Capital and supported by Novo A/S, Canaan Partners, Life Science Angels, and Atheneos Capital. This substantial investment is earmarked for the advancement of ATS907, a selective Rho-kinase inhibitor intended for the topical treatment of glaucoma. Notably, Altheos licensed this promising compound from a Japanese pharmaceutical company and has a broad portfolio of highly effective compounds designed specifically for glaucoma treatment. Overall, Altheos seems to have garnered significant support from key players in the industry, and its focus on pioneering novel treatments for glaucoma positions it well for success in the healthcare and biotechnology sectors. The $12.50 million Series A investment further indicates continued confidence in the company's potential, with Novo Holdings, Canaan Partners, and Bay City Capital demonstrating their ongoing commitment to Altheos' development. This strategic support, combined with the promising pipeline of small molecule drugs, positions Altheos as a compelling player in the quest for innovative glaucoma treatments.